Abstract
We report on 161 patients suffering from inflammatory dermatoses on hands, forearms, and lower legs who had been initially treated with 0.1% difluocortolone valerate. During the maintenance therapy carried out over a period of 3 to 4 weeks, we tested the efficacy of Kamillosan cream vs. 0.25% hydrocortisone, 0.75% fluocortin butyl ester, and 5% bufexamac in a bilateral comparative study. For the indications tested Kamillosan cream showed more or less equieffective therapeutic results as compared to 0.25% hydrocortisone. It is superior, however, to the non-steroidal anti-inflammatory agent 5% bufexamac as well as to 0.75% fluocortin butyl ester, a further glucocorticoid. With regard to neurodermitis, Kamillosan cream not only shows the same therapeutic effect as 0.25% hydrocortisone but is even of marked superiority towards other reference products.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
English Abstract
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Bufexamac / administration & dosage*
-
Bufexamac / therapeutic use
-
Chamomile
-
Clinical Trials as Topic
-
Dermatitis / drug therapy*
-
Dermatitis, Contact / drug therapy
-
Dermatitis, Seborrheic / drug therapy
-
Diflucortolone / administration & dosage
-
Diflucortolone / analogs & derivatives
-
Female
-
Fluocortolone / administration & dosage
-
Fluocortolone / analogs & derivatives*
-
Fluocortolone / therapeutic use
-
Humans
-
Hydrocortisone / administration & dosage*
-
Hydrocortisone / therapeutic use
-
Hydroxamic Acids / administration & dosage*
-
Male
-
Middle Aged
-
Neurodermatitis / drug therapy
-
Oils, Volatile / therapeutic use*
-
Ointments
-
Plant Extracts / therapeutic use*
-
Plants, Medicinal
Substances
-
Hydroxamic Acids
-
Oils, Volatile
-
Ointments
-
Plant Extracts
-
diflucortolone valerate
-
Bufexamac
-
Fluocortolone
-
fluocortin butyl ester
-
Diflucortolone
-
Hydrocortisone